8-K - Kenvue Inc. (0001944048) (Filer)

FWP - Kenvue Inc. (0001944048) (Subject)

424B5 - Kenvue Inc. (0001944048) (Filer)

SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

10-Q - Kenvue Inc. (0001944048) (Filer)

8-K - Kenvue Inc. (0001944048) (Filer)

DEFA14A - Kenvue Inc. (0001944048) (Filer)

DEFA14A - Kenvue Inc. (0001944048) (Filer)

DEF 14A - Kenvue Inc. (0001944048) (Filer)

Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Amit Banati, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 3, 2025, at 6:00 a.m. Eastern Time / 12:00 p.m. Central European Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. is the world's larges

Kenvuers contribute 5,000+ hours of volunteer time to local causes along with building 22,000+ hygiene kits for underserved communities Hygiene kits to feature 110,000+ donated products from iconic brands Neutrogena®, Listerine®, OGX®, Johnson's® Baby and more Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative part of its Healthy Lives Mission. Kenvue Cares Week is a testament to the strong Kenvue commitment to advance the well-being of people and our planet, giving back through voluntee

Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine

Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in

Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced a five-year collaboration with Microsoft which aims to establish a strong foundation for transforming digital operations through advanced Artificial Intelligence (AI) technologies. These technologies include machine-enabled collaboration, predictive analytics, smart agents, digital twins, and generative AI. By advancing predictive and AI-assisted capabilities, Kenvue aims to set new standards for innovation across commercial, operations, and technology practices ultimately delivering enhanced consumer experiences, increased productivity, and sustained growth. Over the next

New campaign introduces new Bond Protein Repair hair line designed to deliver effective bonding repair – at a fraction of the price of prestige brands  SUMMIT, N.J., April 7, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) announces actress and entrepreneur, Shay Mitchell, as the global brand ambassador for OGX®, stepping in as the face of the brand's Fixer character in their new campaign. This collaboration marks an exciting new chapter for OGX®, as the brand leans deeper into its positioning as #1 in hair repairi, with The Fixer as a character embodying that expertise, and leverages the power of science-backed, expert-endorsed innovations to reach more consumers.

The Brand's Latest Mineral Sunscreen AddressesTop Consumer Barriers to Daily Sunscreen Use SUMMIT, N.J., March 31, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE:KVUE) continues to push the boundaries of suncare product development with the launch of the Neutrogena® Ultra Sheer ® Face Liquid Mineral Sunscreen SPF 70. A December 2024 Kenvue research study found that 99% of healthcare providers believe if sunscreen offered better application and aesthetic experiences, patients would use their sunscreen more often1. The new mineral formula addresses these barriers by offering a high SPF with a lightweight, invisible finish. To raise awareness, the #1 suncare brand2 in the U.S. is launching a new campai

Science Behind Iconic Brands, including NEUTROGENA® and AVEENO®, Underscores the Company's Expertise and Commitment to Shaping the Future of Skin Health & Beauty Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida. In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry experts on the effectiveness of formulations behind iconic brands such as

Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as

Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa

Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00

Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously

Deutsche Bank downgraded Kenvue from Buy to Hold and set a new price target of $24.00 from $25.00 previously

Jefferies initiated coverage of Kenvue with a rating of Buy and set a new price target of $27.00

RBC Capital Mkts downgraded Kenvue from Outperform to Sector Perform and set a new price target of $24.00

Citigroup resumed coverage of Kenvue with a rating of Neutral and set a new price target of $21.00

Bernstein initiated coverage of Kenvue with a rating of Underperform and set a new price target of $18.00

William Blair initiated coverage of Kenvue with a rating of Mkt Perform

Goldman resumed coverage of Kenvue with a rating of Neutral and set a new price target of $20.00

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

4 - Kenvue Inc. (0001944048) (Issuer)

3 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine

Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in

Q4 Net Sales Decreased 0.1% to $3.7 Billion; Organic Sales1 Grew 1.7% Q4 Diluted EPS was $0.15; Adjusted Diluted EPS1 was $0.26 FY'24 Net Sales Increased 0.1% to $15.5 Billion; Organic Sales1 Grew 1.5% FY'24 Gross Profit Margin Improved 200 Basis Points and Our Vue Forward Savings Supported Increased Marketing Investment to Fuel Growth FY'24 Diluted EPS was $0.54; Adjusted Diluted EPS1 was $1.14 Provides Outlook for FY'25   Kenvue Inc. (NYSE:KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. "We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we

Company Confirms Receipt of Director Nominees from Starboard Value No Shareholder Action Required at This Time Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today issued the following statement in response to Starboard Value's ("Starboard") submission of four nominees to stand for election to the Kenvue Board of Directors at Kenvue's 2025 Annual Meeting of Shareholders: The Kenvue Board and management team are committed to acting in the best interests of Kenvue and our shareholders. We engage regularly with our shareholders and are open to constructive dialogue with and suggestions from Kenvue shareholders. We note that members o

Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2024 financial results before market open on February 6, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand

Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock. This quarterly dividend is payable on February 26, 2025, to shareholders of record as of the close of business on February 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every d

Net Sales Decreased 0.4% to $3.9 Billion; Organic Growth1 was 0.9% Gross Profit Margin Expansion and Our Vue Forward Savings Fuel Increased Marketing Investment Diluted EPS was $0.20; Adjusted Diluted EPS1 was $0.28 Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal third quarter ended September 29, 2024. "During the third quarter, we continued to drive strong productivity and realize efficiency benefits from Our Vue Forward, which we are reinvesting behind our iconic brands to unleash the full potential of our business and fulfill our commitment to create long-term shareholder value," said Thibaut Mongon, Chief Executive Officer. "This reinvestment

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, will announce its third quarter 2024 financial results before market open on November 7, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage,

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock. This quarterly dividend is payable on November 27, 2024, to shareholders of record as of the close of business on November 13, 2024. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe